Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
Annovis Bio Q3 EPS $(0.22) Beats $(0.32) Estimate
Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap
Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman
Annovis Announces Pricing of $21.0 Million Public Offering
Annovis Bio, Inc. Reports Preliminary Cash and Cash Equivalents of approximately $2.8 million
Annovis Bio, Inc. Stockholders Approve Increase in Authorized Shares to 140,000,000
Annovis Announces Launch of Proposed Public Offering
Annovis Bio Plans To Commence Common Stock Offering; Terms Undisclosed
Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
Annovis Bio Obtains Noncompliance Notice From NYSE
Annovis to Attend the CTAD 2026 with Three Presentations
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
Annovis Bio Consensus Price Target Lowered by 16.67% to $10.71
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA
Roth Capital Maintains Buy on Annovis Bio, Lowers Price Target to $7
Annovis to Host Corporate Update Webinar on September 2, 2026
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
Annovis Bio Q2 EPS $(0.40) Beats $(0.45) Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.